JERUSALEM, May 7, 2019 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces financial results for the three months ended March 31, 2019 and provides a corporate update.
Highlights of the first quarter 2019 and recent weeks include:
- Announced that the last patient completed their final visit in the Company’s pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pill®-Carbidopa/Levodopa (AP-CD/LD) compared with immediate release CD/LD (IR-CD/LD; Sinemet®) as a treatment for the symptoms of advanced Parkinson’s disease (PD);
- Reported positive data from a pharmacokinetic (PK) study of AP-CD/LD 50/500 mg in PD patients, demonstrating that AP-CD/LD when dosed three times per day (TID) met the primary endpoint of reducing plasma levodopa variability when compared to standard oral CD/LD dosed five times per day (p=0.0048);
- Announced that data from the PK study of AP-CD/LD 50/500 mg TID